Physician profile

Anna Gyurjyan

Obstetrics & Gynecology (Nurse Practitioner) · Newport News, VA

NPI 1073578811

$321.02

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$178.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Biofrontera INC. $98.76 2024 Xepi, Bf-Rhodoled, Rhodoled Xl
Novo Nordisk INC $96.24 2022
Optumhealth Care Solutions, LLC $43.31 2024 Vivify Health Care Team Portal 001, Eitan Medical
Lilly USA, LLC $25.39 2021
Xeris Pharmaceuticals, INC. $20.79 2022
Hologic Sales and Service, LLC $19.58 2024 Aptima
Medtronic, INC. $16.95 2023 Minimed 780g

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anna Gyurjyan

$321.02

in general payments reported 2019-2025

Years
2021-2024
Top company
Biofrontera INC.

https://glasscript.com/doctor/10808299/anna-gyurjyan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.